Insulin Resistance & Diabetes
Influence of class III obesity on mode of delivery and perinatal complications in nulliparous women: A matched case-control study
- Gryson R, Bellamkonda S, Asandei D, Dicker P, Malone C, Musa D, Habib SA, Floyd R, O'Malley E, Fullston E, Crimmins E, O'Mahony I, Breathnach FM. Influence of class III obesity on mode of delivery and perinatal complications in nulliparous women: A matched case-control study Int J Gynaecol Obstet
Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation
- Sridhar A, Palmer ES, Craig SL, Krason-Kidzinska E, Irwin N, O'Harte FPM. Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation Diabetes Obes Metab
Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting
- Al Ozairi E, Al Awadhi A, Taghadom E, Al Kandari J, Alsaeed D, Alghanim S, Mashankar A, Le Roux C. Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting BMJ Open
Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group
- Stephens JW, Dhatariya K, Beamish AJ, Pournaras DJ, Miras AD, Raafat N, Noble-Bell G, Cadwallader Buckland R, Mustafa OG. Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group Diabet Med
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5
- Galindo RJ, Aronne LJ, Horn DB, Miras AD, Dunn JP, Cao D, Lee CJ, Karanikas CA, Heine RJ, Falcon BL, Dimitriadis GK. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5 J Endocrinol Invest
Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes: effect sizes and mechanisms
- Chiriacò M, Tricò D, Petrie JR, Gabriel R, Gastaldelli A, Nolan J, Lalic N, Mingrone G, Mari A, Natali A. Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes: effect sizes and mechanisms Diabetologia
Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials
- Ko D, Kim DH, Tan FXN, Ho GJK, Chandra R, Xuan ZZ, Jun ETK, Tang NSY, Yang HS, Koh JWH, Danpanichkul P, Dalakoti M, Syn NL, Wijarnpreecha K, Takahashi H, Zheng MH, Nakajima A, Noureddin M, Muthiah M, Le Roux CW, Siddiqui MS, Ng CH. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials Cell Rep Med
Impact of Metabolic Bariatric Surgery on Weight Loss and Glycemic Control in Adults With Type 1 Diabetes: A Multicenter Retrospective Cohort Study
- van der Meer R, Pazmino S, Steenackers N, van Laar A, Sluis M, Tolenaars L, Rosen J, Hurtado Del Pozo C, le Roux CW, Al Kandari J, Irshad M, Lannoo M, Deleus E, Dillemans B, Van Nieuwenhove Y, van Bon A, Hazebroek E, Al Ozairi E, Hoogma R, Mathieu C, Liem Impact of Metabolic Bariatric Surgery on Weight Loss and Glycemic Control in Adults With Type 1 Diabetes: A Multicenter Retrospective Cohort Study Diabetes Care
Type 1 Diabetes Is a Barrier to Obesity Treatment: Patient Insights From a Mixed-Methods Study
- Al Ozairi E, Alsaeed D, Mondoh A, Taghadom E, Irshad M, Alroudhan D, Kandari JA, Al-Najim W, le Roux CW. Type 1 Diabetes Is a Barrier to Obesity Treatment: Patient Insights From a Mixed-Methods Study J Obes